The recent success story of twice yearly shots of Lenacapavir preventing HIV in over 96 percent of at-risk people and the Gilead granting royalty-free voluntary licenses to six generic pharma globally ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Bill Earl, councilman and planning commissioner, told the crowd that the council is looking at all revenue options for major ...

Gilead has made the decision to withdraw the accelerated approval of Trodelvy (sacituzumab govitecan) for advanced urothelial cancer in the United States.

Guided Therapeutics, Inc. , the maker of the LuViva Advanced Cervical Scan, announced today that its Chinese Partner, Shandong Yaohua Medical Instrument Corporation (SMI), has filed its application ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Neural Concept, the leading end-to-end 3D AI platform that transforms product design with Engineering Intelligence, has announced the opening of a new office in the United States, located in the New ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene i ...